Elicera Therapeutics announces participation in several industry and investor meetings in October and November
Gothenburg, October 5, 2021 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immunooncological treatments focusing on CAR T-cells and oncolytic viruses, announced today that the company will attend the following industry and investor meetings in October and November 2021:
- ESGCT (European Society of Gene & Cell Therapy) Virtual Congress 2021 – 19-21 oktober 2021
Associate Professor Di Yu, Development Manager at Elicera Therapeutics, will present preclinical data for the company's iTANK platform.
- 13th Annual PEGS Europe Summit (Protein & Antibody Engineering Summit) – 2-4 november 2021
Professor Magnus Essand, Chief Scientific Officer at Elicera Therapeutics, will present preclinical data for the company's iTANK platform.
- Investival showcase 2021 – 8-15 november
Jamal El-Mosleh, CEO of Elicera Therapeutics, will attend individual meetings with potential partners and investors.
- Stora Aktiedagen Göteborg – 9 november
Jamal El-Mosleh, CEO of Elicera Therapeutics, will give a company presentation.
- Aktieportföljen Live – 24 november
Jamal El-Mosleh, CEO of Elicera Therapeutics, will give a company presentation.
- Stora Aktiedagen Stockholm – 29 november
Jamal El-Mosleh, CEO of Elicera Therapeutics, will give a company presentation.
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com
About the iTANK platform
The iTANK (immunoTherapies Activated with NAP for efficient Killing) platform is the company's own fully developed technology platform for strengthening and arming CAR T-cells. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating protein (NAP) from the bacterium Helicobacter pylori. Upon activation, NAP has been shown to be able to enhance the function of the CAR T-cell in addition to activating a parallel immune response via CD8 + killer T-cells. It is expected to be able to generate a broad attack against most targets on cancer cells. The iTANK platform is used to strengthen the company's own CAR T cells but can also be applied to other CAR T-cells under development.
About Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T cells in development and activate killer T cells against cancer. The Company’s share (ELIC) is traded on Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail: ca@gwkapital.se, tel: +468-503 000 50.
For more information, please visit www.elicera.com